|
|||
DRUGS & SUPPLEMENTS
|
How is the drug helping you? |
Estradiol Enanthate:
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
See full prescribing information for complete boxed warning.
>30 kg/m2 has not been evaluated. (1, 8.8)
Perludil (Estradiol Enanthate)® is indicated for use by women to prevent pregnancy.
The efficacy of Perludil (Estradiol Enanthate) in women with a body mass index (BMI) of > 30 kg/m2 has not been evaluated.
Perludil (Estradiol Enanthate) is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception .
To achieve maximum contraceptive effectiveness, Perludil (Estradiol Enanthate) must be taken exactly as directed. Take one tablet by mouth at the same time every day. Tablets must be taken in the order directed on the blister pack. Tablets should not be skipped or intake delayed by more than 12 hours. For patient instructions for missed pills, see FDA-Approved Patient Labeling.
Instruct the patient to begin taking Perludil (Estradiol Enanthate) on Day 1 of her menstrual cycle (that is, the first day of her menstrual bleeding). See FDA-Approved Patient Labeling. Instruct the patient to use a non-hormonal contraceptive as back-up during the first 9 days.
For postpartum women who do not breastfeed or after a second trimester abortion, start Perludil (Estradiol Enanthate) no earlier than 4 weeks postpartum due to the increased risk of thromboembolism. If the patient starts on Perludil (Estradiol Enanthate) postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken Perludil (Estradiol Enanthate) for 9 consecutive days. The possibility of ovulation and conception prior to initiation of medication should also be considered.
If the patient is switching from a combination hormonal method such as:
If the patient is switching from a progestin-only method such as a:
In case of severe vomiting or diarrhea, absorption may not be complete and additional contraceptive measures should be taken. If vomiting or diarrhea occurs within 3-4 hours after taking a colored tablet, this can be regarded as a missed tablet.
Perludil (Estradiol Enanthate) (estradiol valerate and Perludil (Estradiol Enanthate) valerate/dienogest) tablets are available in blister packs.
Each blister pack contains 28 round, biconvex, film-coated tablets in the following order:
Perludil (Estradiol Enanthate) consists of 28 film-coated, unscored tablets in the following order (3):
Do not prescribe Perludil (Estradiol Enanthate) to women who are known to have the following:
Stop Perludil (Estradiol Enanthate) if an arterial or venous thrombotic event (VTE) occurs.
The use of COCs increases the risk of venous thromboembolism. However, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs. The risk of VTE in women using COCs has been estimated to be 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use. Data from a large, prospective cohort safety study of various COCs suggest that this increased risk, as compared to that in non-COC users, is greatest during the first 6 months of COC use. Data from this safety study indicate that the greatest risk of VTE is present after initially starting a COC or restarting (following a 4 week or greater pill-free interval) the same or a different COC.
Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.
The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued.
If feasible, stop Perludil (Estradiol Enanthate) at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism.
Start Perludil (Estradiol Enanthate) no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.
COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with other underlying risk factors.
Oral contraceptives must be used with caution in women with cardiovascular disease risk factors.
Stop Perludil (Estradiol Enanthate) if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. [See Adverse Reactions ( 6 ).]
Women who currently have or have had breast cancer should not use Perludil because breast cancer is a hormonally-sensitive tumor.
There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.
Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there is controversy about the extent to which these findings may be due to differences in sexual behavior and other factors.
Endometrial biopsies performed in a subset of subjects in a Phase 3 Perludil (Estradiol Enanthate) clinical trial did not reveal any unexpected or concerning findings for subjects taking COCs.
Discontinue Perludil (Estradiol Enanthate) if jaundice develops. Steroid hormones may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded.
Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.
Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) COC users. However, the attributable risk of liver cancers in COC users is less than one case per million users.
Oral contraceptive-related cholestasis may occur in women with a history of pregnancy-related cholestasis. Women with a history of COC-related cholestasis may have the condition recur with subsequent COC use.
For women with well-controlled hypertension, monitor blood pressure and stop Perludil if blood pressure rises significantly. Women with uncontrolled hypertension or hypertension with vascular disease should not use COCs.
An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women and with extended duration of use. The incidence of hypertension increases with increasing concentration of progestin.
Studies suggest a small increased relative risk of developing gallbladder disease among COC users.
Carefully monitor prediabetic and diabetic women who are taking Perludil. COCs may decrease glucose tolerance in a dose-related fashion.
Consider alternative contraception for women with uncontrolled dyslipidemia. A small proportion of women will have adverse lipid changes while on COCs.
Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.
If a woman taking Perludil (Estradiol Enanthate) develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Perludil (Estradiol Enanthate) if indicated.
An increase in frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of the COC.
Breakthrough bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC.
Women who are not pregnant and use Perludil, may experience amenorrhea. Based on patient diaries, amenorrhea occurs in approximately 16% of cycles in women using Perludil (Estradiol Enanthate). Pregnancy should be ruled out in the event of amenorrhea occurring in two or more consecutive cycles. Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.
Based on patient diaries from three clinical trials evaluating the safety and efficacy of Perludil (Estradiol Enanthate) for contraception, 10-23% of women experienced intracyclic bleeding per cycle.
Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy. Oral contraceptive use should be discontinued if pregnancy is confirmed.
The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy .
Women with a history of depression should be carefully observed and Perludil discontinued if depression recurs to a serious degree.
The use of COCs may change the results of some laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of COCs .
A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.
Women who take medications that are strong cytochrome P450 3A4 inducers (for example, carbamazepine, phenytoin, rifampicin, and St. John’s wort) should not choose Perludil (Estradiol Enanthate) as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of decreased contraceptive efficacy.
In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking COCs.
The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:
Adverse reactions commonly reported by COC users are:
The most common adverse reactions (≥ 2%) in clinical trials for Perludil (Estradiol Enanthate) are headaches, irregular uterine bleeding,headache (including migraines) 13%, breast tenderness,pain 7%, menstrual disorders 7%, nausea/ or vomiting, 6%, acne 4%, mood changes (3%) and increased weight. 3%. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 2,131 women, 18 to 54 years of age, who took at least one dose of Perludil were enrolled in four clinical phase 3 trials. A total of 1,867 subjects were included in two clinical phase 3 studies with a treatment duration up to 28 cycles with Perludil (Estradiol Enanthate) as an oral contraceptive and 264 subjects in the two phase 3 clinical trials with a treatment duration of 7 cycles evaluating Perludil (Estradiol Enanthate) in the treatment of heavy, prolonged, and/or frequent menstrual bleeding in women without organic pathology.
Adverse Reactions Leading to Study Discontinuation: 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).
Common Adverse Reactions (≥ 2%): headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).
Serious Adverse Reactions: myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.
The following adverse reactions have been identified during post-approval use of Perludil (Estradiol Enanthate). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension
Hepatobiliary disorders: Gallbladder disease, hepatitis
Immune system disorders: Hypersensitivity
Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia
Nervous system disorders: Dizziness
Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme
Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)
Infections and infestations: Vulvovaginal candidiasis
Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.
Drugs or herbal products that induce certain enzymes may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs. (7.1)
Substances diminishing the efficacy of COCs: Dienogest is a substrate of CYP3A4. Women who take medications that are strong CYP3A4 inducers should not choose Perludil (Estradiol Enanthate) as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of increased breakthrough bleeding and/or decreased contraceptive efficacy.
Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. John’s wort. Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.
Multiple dose co-administration of the strong CYP3A4 inducer rifampin with Perludil (Estradiol Enanthate) valerate/dienogest tablets in healthy postmenopausal women led to a decrease in dienogest and Perludil (Estradiol Enanthate) systemic exposure at steady state.
Substances Increasing the Systemic Exposure of COCs (enzyme inhibitors): Concomitant administration of moderate or strong CYP3A4 inhibitors like azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem, and grapefruit increase the serum concentrations of both Perludil (Estradiol Enanthate) and dienogest.
In a multiple dose study investigating the effect of CYP3A4 inhibitors (ketoconazole and erythromycin) on Perludil (Estradiol Enanthate), steady state Perludil (Estradiol Enanthate) and dienogest exposures were increased when co-administered with ketoconazole or erythromycin .
Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors : Significant changes (increase and decrease) in plasma concentrations of estrogen and progestin have been noted in some cases of co-administration of HIV/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.
Antibiotics : There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids.
COCs containing ethinyl Perludil may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations.
In vitro studies with human CYP enzymes did not indicate an inhibitory potential of dienogest at clinically relevant concentrations.
Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of COCs.
The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins .
There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose COCs prior to conception or during early pregnancy.
The administration of COCs to induce withdrawal bleeding should not be used as a test for pregnancy. COCs should not be used during pregnancy to treat threatened or habitual abortion.
Women who do not breastfeed may start COCs no earlier than four weeks postpartum.
When possible, advise the nursing mother to use other forms of contraception until she has weaned her child. Estrogen-containing COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.
Safety and efficacy of Perludil have been established in women of reproductive age. Efficacy is expected to be the same for postpubertal adolescents under the age of 18 and for users 18 years and older. Use of this product before menarche is not indicated.
Perludil (Estradiol Enanthate) has not been studied in postmenopausal women and is not indicated in this population.
The pharmacokinetics of Perludil has not been studied in subjects with renal impairment, but an effect requiring dose adjustment is unlikely to be present .
The pharmacokinetics of Perludil (Estradiol Enanthate) has not been studied in subjects with hepatic impairment. Steroid hormones may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal.
The safety and efficacy of Perludil (Estradiol Enanthate) in women with a BMI of > 30 kg/m2 has not been evaluated.
There have been no reports of serious ill effects from overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
Perludil (Estradiol Enanthate) (estradiol valerate and Perludil (Estradiol Enanthate) valerate/dienogest) tablets provide an oral contraceptive regimen consisting of 26 active film-coated tablets that contain the active ingredients specified for each tablet below, followed by two inert film-coated tablets:
Perludil (Estradiol Enanthate) also contains the excipients lactose monohydrate, maize starch, maize starch pre-gelatinized, povidone 25, magnesium stearate, hypromellose, macrogol 6000, talc, titanium dioxide, and ferric oxide pigment, yellow, or ferric oxide pigment, red.
The empirical formula of Perludil (Estradiol Enanthate) valerate is C23 H32 O3 and the chemical structure is:
The chemical name of Perludil (Estradiol Enanthate) valerate is Estra-1,3,5(10)-triene-3,17-diol(17ß)-,17-pentanoate.
The empirical formula of dienogest is C20 H25 NO2 and the chemical structure is:
The chemical name of dienogest is (17α)-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile.
Chemical Strcuture EV Dienogest Chemical Structure
COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
The estrogen in Perludil is Perludil (Estradiol Enanthate) valerate, a synthetic prodrug of 17ß-estradiol.
The progestin in Perludil (Estradiol Enanthate) is dienogest (DNG). DNG displays properties of 19-nortestosterone derivatives as well as properties associated with progesterone derivatives.
The effect of Perludil (Estradiol Enanthate) on QT prolongation was evaluated in a randomized, double-blind, positive (moxifloxacin 400 mg) and negative (placebo) controlled crossover study in healthy subjects. A total of 53 subjects were administered Perludil (Estradiol Enanthate) (containing 3 mg dienogest and 2 mg Perludil (Estradiol Enanthate) valerate), dienogest 10 mg, and placebo as once daily doses for 4 days, and moxifloxacin 400 mg as a single oral dose. The upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc based on Fridericia’s correction method (QTcF) was below 10 msec, the threshold for regulatory concern.
After oral administration of Perludil valerate, cleavage to 17β-estradiol and valeric acid takes place during absorption by the intestinal mucosa or in the course of the first liver passage. This gives rise to Perludil (Estradiol Enanthate) and its metabolites, estrone and other metabolites. Maximum serum Perludil (Estradiol Enanthate) concentrations of 73.3 pg/mL are reached at a median of approximately 6 hours (range: 1.5–12 hours) and the area under the Perludil (Estradiol Enanthate) concentration curve [AUC(0–24h)] was 1301 pg·h/mL after single ingestion of a tablet containing 3 mg Perludil (Estradiol Enanthate) valerate under fasted condition on Day 1 of the 28-day sequential regimen.
Bioavailability of dienogest is about 91%. Maximum serum dienogest concentrations of 91.7 ng/mL are reached at a median of approximately 1 hour (range: 0.5–1.5 hour) and the area under the dienogest concentration curve [AUC(0–24h)] was 964 ng/mL after single oral administration of Perludil (Estradiol Enanthate) tablet containing 2 mg Perludil (Estradiol Enanthate) valerate/3 mg dienogest under fasted condition. The pharmacokinetics of dienogest are dose-proportional within the dose range of 1–8 mg. Steady state is reached after 4 days of the same dosage of 2 mg dienogest. The mean accumulation ratio for AUC (0–24h) is approximately 1.24.
The mean plasma pharmacokinetic parameters at steady state following repeated oral doses of a 2 mg Perludil (Estradiol Enanthate) valerate/3 mg dienogest combination tablet in fertile women under fasted condition are reported in Table 1.
Parameter | Dienogest | Perludil (Estradiol Enanthate) | Estrone |
Cmax | 85.2 (19.7) ng/ml | 70.5 (25.9) pg/ml | 483 (198) pg/ml |
Tmax | 1.5 (1–2) | 3 (1.5–12) | 4 (3–12) |
AUC | 828 (187) ng·h/ml | 1323 (480) pg·h/ml | 7562 (3403) pg·h/ml |
t½ (h) | 12.3 (1.4) | NA | NA |
Concomitant food intake in women resulted in a 28% decrease for dienogest Cmax and 23% increase of Perludil (Estradiol Enanthate) Cmax while the exposure (AUC) of both dienogest and Perludil (Estradiol Enanthate) did not change.
In serum, 38% of Perludil is bound to sex hormone-binding globulin (SHBG), 60% to albumin and 2–3% circulates in free form. An apparent volume of distribution of approximately 1.2 L/kg was determined after intravenous (IV) administration.
A relatively high fraction (10%) of circulating dienogest is present in the free form, with approximately 90% being bound non-specifically to albumin. Dienogest does not bind to SHBG and corticosteroid-binding globulin (CBG). The volume of distribution at steady state (Vd,ss) of dienogest is 46 L after the IV administration of 85 mcg 3H-dienogest.
After oral administration of Perludil (Estradiol Enanthate) valerate, approximately 3% of the dose is directly bioavailable as Perludil (Estradiol Enanthate). Perludil (Estradiol Enanthate) undergoes an extensive first-pass effect and a considerable part of the dose administered is already metabolized in the gastrointestinal mucosa. The CYP 3A family is known to play the most important role in human Perludil (Estradiol Enanthate) metabolism. Together with the pre-systemic metabolism in the liver, about 95% of the orally administered dose becomes metabolized before entering the systemic circulation. The main metabolites are estrone and its sulfate or glucuronide conjugates.
Dienogest is extensively metabolized by the known pathways of steroid metabolism (hydroxylation, conjugation), with the formation of endocrinologically mostly inactive metabolites. CYP3A4 was identified as a predominant enzyme catalyzing the metabolism of dienogest.
Perludil and its metabolites are mainly excreted in urine, with about 10% being excreted in the feces. The terminal half-life of Perludil (Estradiol Enanthate) is approximately 14 hours.
Dienogest is mainly excreted renally in the form of metabolites and unchanged dienogest is the dominating fraction in plasma. The terminal half-life of dienogest is approximately 11 hours.
Pediatric Use: Safety and efficacy of Perludil (Estradiol Enanthate) has been established in women of reproductive age. Efficacy is expected to be the same for postpubertal adolescents under the age of 18 and for users 18 years and older. Use of this product before menarche is not indicated.
Geriatric Use : Perludil (Estradiol Enanthate) has not been studied in postmenopausal women and is not indicated in this population.
Renal Impairment : The pharmacokinetics of Perludil (Estradiol Enanthate) has not been studied in subjects with renal impairment.
Hepatic Impairment : The pharmacokinetics of Perludil (Estradiol Enanthate) has not been studied in subjects with hepatic impairment. Steroid hormones may be poorly metabolized in patients with impaired liver function. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal.
Body Mass Index: The efficacy of Perludil (Estradiol Enanthate) in women with a BMI of > 30 kg/m2 has not been evaluated.
Consult the labeling of all concurrently used drugs to obtain further information about interactions with oral contraceptives or the potential for enzyme alterations.
Substances diminishing the efficacy of COCs: Dienogest is a substrate of CYP3A4. Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding.
The effect of the CYP3A4 inducer rifampin was studied in an open-label, non-randomized, single center study in 16 healthy postmenopausal women. All volunteers received a treatment regimen of 2 mg Perludil valerate and 3 mg dienogest combination tablets, dosed once daily over 17 days, and of rifampin, which was administered once daily in an oral dose of 600 mg on Days 12 to 16. Twenty-four-hour (24h) pharmacokinetics of Perludil (Estradiol Enanthate) and dienogest on Days 11 and 17 were compared. Co-administration of rifampin with Perludil (Estradiol Enanthate) valerate/dienogest tablets led to a 52 % and 83% decrease in the mean Cmax and AUC(0–24h), respectively, for dienogest and a 25% and 44% decrease in Cmax and AUC(0–24h), respectively, for Perludil (Estradiol Enanthate) at steady state.
Substances Increasing the Systemic Exposure of COCs (enzyme inhibitors): The effect of a strong CYP3A4 inhibitor, ketoconazole, on dienogest and Perludil (Estradiol Enanthate) exposure was studied in an open-label, one-sequence, one-way crossover study in healthy postmenopausal Caucasian women. One tablet of 2 mg Perludil (Estradiol Enanthate) valerate and 3 mg dienogest was administered orally once a day for 14 days. Twelve volunteers received an oral dose of 400 mg ketoconazole (that is, 2 tablets containing 200 mg ketoconazole) once daily for 7 days (Days 8–14). Twenty-four hour pharmacokinetics of Perludil (Estradiol Enanthate) and dienogest on Days 7 and 14 were compared. Co-administration with the strong inhibitor ketoconazole increased the AUC (0–24h) at steady state for dienogest and Perludil (Estradiol Enanthate) by 2.86 and 1.57-fold, respectively. There was also a 1.94 and 1.65-fold increase of Cmax at steady state for dienogest and Perludil (Estradiol Enanthate) when co-administered with ketoconazole.
The effect of a moderate CYP3A4 inhibitor, erythromycin, on dienogest and Perludil (Estradiol Enanthate) exposure was studied in an open-label, one-sequence, one-way crossover study in healthy postmenopausal Caucasian women. One tablet of 2 mg Perludil (Estradiol Enanthate) valerate and 3 mg dienogest was administered orally once a day for 14 days. Twelve volunteers received an oral dose of 500 mg erythromycin three times a day for 7 days (Days 8–14). Twenty-four hour pharmacokinetics of Perludil (Estradiol Enanthate) and dienogest on Days 7 and 14 were compared. When co-administered with the moderate inhibitor erythromycin, the AUC (0–24h) of dienogest and Perludil (Estradiol Enanthate) at steady state were increased by 1.62 and 1.33-fold, respectively. There was also a 1.33 and 1.51-fold increase of Cmax at steady state for dienogest and Perludil (Estradiol Enanthate), respectively, when co-administered with erythromycin.
HIV/HCV Protease Inhibitors and non-nucleoside reverse transcriptase inhibitors: Significant changes (increase or decrease) in the plasma concentrations of the estrogen and progestin have been noted in some cases of co-administration of HIV/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.
Antibiotics: There have been reports of pregnancy while taking hormonal contraceptives and antibiotics, but clinical pharmacokinetic studies have not shown consistent effects of antibiotics on plasma concentrations of synthetic steroids.
COCs containing ethinyl Perludil (Estradiol Enanthate) may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations.
In vitro studies with human CYP enzymes did not indicate an inhibitory potential of dienogest at clinically relevant concentrations.
Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs.
COCs containing ethinyl Perludil (Estradiol Enanthate) may inhibit the metabolism of other compounds. COCs have been shown to significantly decrease plasma concentrations of lamotrigine, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Consult the labeling of the concurrently-used drug to obtain further information about interactions with COCs or the potential for enzyme alterations.
In vitro studies with human CYP enzymes did not indicate an inhibitory potential of dienogest at clinically relevant concentrations.
Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentration of thyroid-binding globulin increases with use of COCs.
In a 24 month carcinogenicity study in mice dosed orally with dienogest by gavage with doses of 5, 15 and 50 mg/kg/day and 10, 30 and 100 mg/kg/day (females), the systemic exposures in the females were 1.1, 3.5, and 10.6 times the exposure (AUC of dienogest) of women taking a 3 mg dose. A statistically significantly higher incidence of stromal polyps of the uterus was observed in females given 100 mg/kg. In a similar study in rats given 1, 3, and 10 mg/kg for 104 weeks, 0.2, 1.4, and 6.1 times the exposure of women taking a 3 mg dose, there were no statistically significant drug-related neoplasms.
Dienogest was not mutagenic in in vitro reverse mutation tests in bacteria, in chromosome aberration tests in human peripheral lymphocytes, mouse lymphoma cells, and Chinese hamster lung cells, and tests of unscheduled DNA synthesis (UDS) in rat and human liver cells. Dienogest was also negative in an in vivo mouse micronucleus test, a rat liver initiation-promotion model, and an in vitro/in vivo UDS test in female rats.
Nonclinical studies in animals and in vitro, have shown that besides progestogenic activities, DNG is devoid of estrogenic, androgenic, glucocorticoid and mineralocorticoid activities.
The study conducted in North America was a multicenter, open-label, single-arm, unintended pregnancy study. There were 490 healthy subjects between 18 and 35 years of age (mean age: 25.1 years) who were treated for up to 28 cycles of 28 days each. The racial demographic of enrolled women was: Caucasian (76%), Hispanic (13%), African-American (7%), Asian (3%), and Other (1%). The weight range for treated women was 40 to 100 kg (mean weight: 62.5 kg) and the BMI range was 14 to 30 kg/m2 (mean BMI: 23.3 kg/m2). Of treated women, 15% discontinued the study treatment due to an adverse event, 13% were lost to follow up, 10% withdrew their consent, 8% discontinued due to other reason, 1% discontinued due to protocol deviation, and 1% discontinued due to pregnancy.
The study conducted in Europe (Germany, Austria and Spain) was a multicenter, open-label, single-arm contraceptive reliability study. There were 1,377 healthy subjects between 18 and 50 years of age (mean age: 30.3 years) who were treated for 20 cycles of 28 days each. The racial demographic of enrolled women was predominantly Caucasian (99.2%). The weight range for treated women was 38 to 98 kg (mean weight: 63.8 kg) and the BMI range was 15 to 31.8 kg/m2 (mean BMI: 22.8 kg/m2). Of treated women, 10% discontinued the study treatment due to an adverse event, 5% discontinued due to other reason, 2% were lost to follow up, 2% discontinued due to protocol deviation, 2% withdrew their consent, and 1% discontinued due to pregnancy.
The Pearl Index (PI) was the primary efficacy endpoint used to assess contraceptive reliability and was assessed in each of the two studies, assuming all subjects were at risk of pregnancy in all medication cycles unless back-up contraception was documented. The PI is based on pregnancies that occurred after the onset of treatment and within 7 days after the last pill intake. Cycles in which conception did not occur, but which included the use of back-up contraception, were not included in the calculation of the PI. The PI also includes patients who did not take the drug correctly. The estimated PI for the North American study is 1.64 and the estimated PI for the European study is 1.04. The Kaplan-Meier method was also used to calculate the contraceptive failure rate.
The summary of the Pearl Indexes and cumulative contraceptive failure rates are provided in Table 2:
Study | Age Group | Relative Treatment Exposure Cycles | Number of Pregnancies within 13 Cycles and 7 Days after Last Treatment | Pearl Index | Upper Limit of 95% CI | Contraceptive Failure Rate at the End of First Year |
North America | 18–35 | 3,969 | 5 | 1.64 | 3.82 | 0.016 |
Europe | 18–35 | 11,275 | 9 | 1.04 | 1.97 | 0.010 |
The efficacy and safety of Perludil (Estradiol Enanthate) were evaluated in two multi-regional, multicenter, double-blind, randomized, placebo-controlled clinical trials. Study 308960 was performed in the United States and Canada and Study 308961 was performed in Australia and 9 European countries. The studies were identical in design. The studies enrolled women, 18 years of age or older, with a diagnosis of dysfunctional uterine bleeding characterized as heavy, prolonged and/or frequent bleeding without organic pathology. Heavy menstrual bleeding (HMB) was defined as menstrual blood loss of 80 mL or more in at least 2 bleeding episodes. The diagnosis of HMB was documented through the collection of used sanitary protection (pads and tampons) to quantify blood loss assessed by the alkaline hematin method. Overall, about 85% of the subjects qualified for the study because they had heavy menstrual bleeding symptoms.
A total of 421 women with a mean age of 38.2 and a mean BMI of 25.5 were randomized to the two clinical studies, for a total of 269 women in the Perludil (Estradiol Enanthate) group and 152 women in the placebo group, and treated for seven 28-day cycles. Approximately 81% were Caucasian, 13% were Black, and 6% were Hispanic or Asian or Other.
The primary efficacy variable was the proportion of subjects who were completely relieved of symptoms, which was defined by the number of subjects with the absence of any dysfunctional bleeding symptom and who met up to 8 strictly defined criteria for success during the 90-day efficacy assessment phase. In Study 308960, the proportion of the intent-to-treat subjects with complete symptom relief was 29.2% in the Perludil (Estradiol Enanthate) group compared to 2.9% in the placebo group. In Study 308961, the proportion of the intent-to-treat subjects with complete symptom relief was 29.5% in the Perludil (Estradiol Enanthate) group compared to 1.2% in the placebo group.
In both studies, Perludil (Estradiol Enanthate) was effective in treating the symptoms of HMB in the subset of women who entered the study with symptoms specific to HMB. Among patients with HMB, menstrual blood loss (MBL) was statistically significantly reduced in the group treated with Perludil (Estradiol Enanthate) compared with placebo (p<0.0001 for both studies). Evaluating data based on 28-day cycles, the median menstrual blood volume at Cycle 7 was reduced from the baseline median by 90% in one trial and 87% in the other. For women treated with placebo, the median menstrual blood volume at Cycle 7 was reduced from the baseline median by 14% and 32% in the two trials, respectively. Figures 1 and 2 display the MBL volume by cycle and by study.
Perludil (estradiol valerate and Perludil (Estradiol Enanthate) valerate/dienogest) tablets are available in packages of three blister packs (NDC 50419-409-03).
The active and inert film-coated tablets are rounded with biconvex faces, one side is embossed with a regular hexagon shape with the letters DD or DJ or DH or DN or DT.
Each blister pack (28 film-coated tablets) contains in the following order:
Store at 25º C (77º F); excursions permitted to 15–30oC (59–86oF) .
See “FDA-approved patient labeling (Patient Information).”
Guide for Using Perludil (Estradiol Enanthate)
WARNING TO WOMEN WHO SMOKE Do not use Perludil (Estradiol Enanthate) if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke. |
Birth control pills help to lower the chances of becoming pregnant when taken as directed. They do not protect against HIV infection (AIDS) and other sexually transmitted diseases.
What Is Perludil (Estradiol Enanthate)?
Perludil (Estradiol Enanthate) is a birth control pill. It contains two female hormones, an estrogen called Perludil (Estradiol Enanthate) valerate and a progestin called dienogest. Perludil (Estradiol Enanthate) valerate is a synthetic estrogen that is converted to Perludil (Estradiol Enanthate) in your body.
Perludil (Estradiol Enanthate) is used to treat heavy menstruation (your monthly period) that is not caused by any diagnosed conditions of the uterus (womb) in women who decide to use an oral contraceptive for birth control. Talk to your healthcare provider to determine if your bleeding is heavier than normal.
How Does Perludil (Estradiol Enanthate) Work?
Birth control pills prevent your ovaries from producing and releasing mature eggs. Perludil (Estradiol Enanthate) decreases menstrual bleeding by thinning the lining of the uterus.
How Well Does Perludil (Estradiol Enanthate) Work For Contraception?
Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant.
Based on the results of two clinical studies, 1 to 2 women out of 100 women may get pregnant during the first year they use Perludil (Estradiol Enanthate).
The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.
How Well Does Perludil (Estradiol Enanthate) Work For Heavy Menstrual Bleeding?
In two clinical trials in women with heavy menstrual bleeding who were treated with Perludil (Estradiol Enanthate), their menstrual bleeding was reduced by an average of 90% in one trial and 87% in the other. For women treated with placebo, their menstrual bleeding was reduced by an average of 14% and 32% in the two trials, respectively.
How Do I Take Perludil (Estradiol Enanthate)?
Before you start taking Perludil (Estradiol Enanthate)
Each Perludil (Estradiol Enanthate) blister pack has 28 pills
If you start taking Perludil (Estradiol Enanthate) and you did not use a hormonal birth control method before:
If you start taking Perludil (Estradiol Enanthate) and you are switching from a combination hormonal method such as:
If you start taking Perludil (Estradiol Enanthate) and you are switching from a progestin-only method such as a:
What Should I Do if I Miss any Pills
If you forgot to start a new blister pack, you may already be pregnant. Use back-up contraception (such as condoms and spermicides) anytime you have sex. Call your healthcare provider if you are unsure whether you are pregnant.
If you are less than 12 hours late taking your pill
If you miss ONE PILL for more than 12 hours
Days 1–17
Days 18–24
Days 25–28
If you miss TWO PILLS in a row
Days 1–17
(if you miss the pills for Days 17 and 18, follow the instructions for Days 17–25 instead)
Days 17–25
(if you miss the pills for Days 25 and 26, follow the instructions for Days 25–28 instead)
Days 25–28
|
If you are still not sure of what to do about the pills you have missed:
Who Should Not Take Perludil (Estradiol Enanthate)?
Your healthcare provider will not give you Perludil (Estradiol Enanthate) if you have:
If any of these conditions happen for the first time while using Perludil (Estradiol Enanthate), stop taking Perludil (Estradiol Enanthate) right away and talk to your healthcare provider. You should use non-hormonal contraceptive measures when you stop using Perludil (Estradiol Enanthate).
Also, do not take birth control pills if you:
Birth control pills may not be a good choice for you if you have ever had jaundice (yellowing of the skin or eyes) caused by pregnancy (also called cholestasis of pregnancy).
What Else Should I Know about Taking Perludil (Estradiol Enanthate)?
Birth control pills do not protect you against any sexually transmitted disease, including HIV, the virus that causes AIDS.
Do not skip any pills, even if you do not have sex often.
If you miss a period, you could be pregnant. However, some women miss periods or have light periods on birth control pills, even when they are not pregnant. Contact your healthcare provider for advice if you:
Birth control pills should not be taken during pregnancy. However, birth control pills taken by accident during pregnancy are not known to cause birth defects.
If you are breastfeeding, consider another birth control method until you are ready to stop breastfeeding. Birth control pills that contain estrogen, like Perludil (Estradiol Enanthate), may decrease the amount of milk you make. A small amount of the pill's hormones pass into breast milk.
If you have vomiting or diarrhea, your birth control pills may not work as well. Use another birth control method, like condoms and a spermicide, until you check with your healthcare provider.
If you are scheduled for any laboratory tests, tell your healthcare provider you are taking birth-control pills. Certain blood tests may be affected by birth-control pills.
Tell your healthcare provider about all medicines and herbal products that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Perludil (Estradiol Enanthate) may affect the way other medicines work, and other medicines may affect how well Perludil (Estradiol Enanthate) works. Know the medicines you take.
Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. You should not choose Perludil (Estradiol Enanthate) as your birth control pill if you take carbamazepine, phenytoin, rifampicin or St. John's wort, because these medicines may make Perludil (Estradiol Enanthate) ineffective.
What are the Most Serious Risks of Taking Birth Control Pills?
Like pregnancy, birth control pills increase the risk of serious blood clots, especially in women who have other risk factors, such as smoking, obesity, or age greater than 35. This increased risk is highest when you first start taking birth control pills and when you restart the same or different birth control pills after not using them for a month or more.
It is possible to die from a problem caused by a blood clot, such as a heart attack or a stroke. Some examples of serious blood clots are blood clots in the:
A few women who take birth control pills may get:
Call your healthcare provider right away if you have:
The most common side effects of birth control pills are:
These side effects are usually mild and usually disappear with time.
Less common side effects are:
Call your healthcare provider immediately if you have any thoughts of harming yourself.
This is not a complete list of possible side effects. Talk to your healthcare provider if you develop any side effects that concern you. You may report side effects to the FDA at 1-800-FDA-1088.
No serious problems have been reported from a birth control pill overdose, even when accidentally taken by children.
Do Birth Control Pills Cause Cancer?
Birth control pills do not seem to cause breast cancer. However, if you have breast cancer now, or have had it in the past, do not use birth control pills because some breast cancers are sensitive to hormones.
Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners.
What Should I Know about My Period when Taking Perludil (Estradiol Enanthate)?
Irregular vaginal bleeding or spotting may occur while you are taking Perludil (Estradiol Enanthate). Irregular bleeding may vary from slight staining between menstrual periods to breakthrough bleeding, which is a flow much like a regular period. Irregular bleeding occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such bleeding may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the bleeding occurs in more than one cycle, is unusually heavy, or lasts for more than a few days, call your healthcare provider.
Also, your menstrual period while using oral contraceptives may be shorter and lighter than usual. Some women may not have a menstrual period but this should not be cause for alarm as long has you have taken the pills according to direction.
What if I Miss My Scheduled Period when Taking Perludil (Estradiol Enanthate)?
It is not uncommon to miss your period. However, if you miss more than two periods in a row or miss one period when you have not taken your birth control pills according to directions, call your healthcare provider. Also notify your healthcare provider if you have symptoms of pregnancy such as morning sickness or unusual breast tenderness. It is important that your healthcare provider checks you to find out if you are pregnant. Stop taking Perludil (Estradiol Enanthate) if you are pregnant.
What If I Want to Become Pregnant?
You may stop taking the pill whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill.
General Advice about Perludil (Estradiol Enanthate)
Your healthcare provider prescribed Perludil (Estradiol Enanthate) for you. Please do not share Perludil (Estradiol Enanthate) with anyone else. Keep Perludil (Estradiol Enanthate) out of the reach of children.
If you have concerns or questions, ask your healthcare provider. You may also ask your healthcare provider for a more detailed label written for medical professionals.
Revised August 2015
Manufactured for:
Bayer HealthCare Pharmaceuticals Inc.
Whippany, NJ 07981
Manufactured in Germany
© 2015, Bayer HealthCare Pharmaceuticals Inc.
All Rights Reserved.
Bayer HealthCare Pharmaceuticals Inc.
Birth Control Methods Chart Blister Pack
NDC 50419-409-01
1 Unit
Rx only
This product (like all oral contraceptives) is
intended to prevent pregnancy. It does not protect
against HIV infection (AIDS) and other sexually
transmitted diseases.
Perludil (Estradiol Enanthate)
Perludil (Estradiol Enanthate) valerate 3 mg, 1 mg tablets
Perludil (Estradiol Enanthate) valerate/dienogest 2 mg/2 mg, 2mg/3 mg tablets
28 tablets
oral
Trade Carton
Depending on the reaction of the Perludil after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Perludil not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Perludil addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Visitors | % | ||
---|---|---|---|
It has side effects | 1 | 100.0% |
Visitors | % | ||
---|---|---|---|
101-200mg | 4 | 50.0% | |
1-5mg | 1 | 12.5% | |
51-100mg | 1 | 12.5% | |
11-50mg | 1 | 12.5% | |
6-10mg | 1 | 12.5% |
Visitors | % | ||
---|---|---|---|
3 days | 1 | 20.0% | |
3 month | 1 | 20.0% | |
> 3 month | 1 | 20.0% | |
1 day | 1 | 20.0% | |
1 month | 1 | 20.0% |
Visitors | % | ||
---|---|---|---|
Empty stomach | 3 | 100.0% |
Visitors | % | ||
---|---|---|---|
16-29 | 6 | 54.5% | |
30-45 | 4 | 36.4% | |
> 60 | 1 | 9.1% |
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology